NCT04851613 2026-04-02
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Laekna Limited
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT04374630 2025-09-10
PROFECTA-II
Laekna Limited
Phase 2 Completed
NCT04060394 2024-10-10
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Laekna Limited
Phase 1/2 Completed
NCT05390710 2024-10-10
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
Laekna Limited
Phase 1 Completed
NCT02177682 2021-08-11
Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
Novartis
Phase 1 Terminated
NCT01531894 2019-07-09
Continuation Study of the Oral AKT Inhibitor GSK2110183
Novartis
Phase 2 Completed
NCT02240212 2017-04-11
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
Novartis
Phase 1 Completed
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT02235740 2016-05-04
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
Novartis
Phase 1 Terminated